US5217996A
(en)
*
|
1992-01-22 |
1993-06-08 |
Ciba-Geigy Corporation |
Biaryl substituted 4-amino-butyric acid amides
|
AR002945A1
(es)
*
|
1994-11-15 |
1998-05-27 |
Bayer Corp |
Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos
|
WO1996026183A1
(en)
*
|
1995-02-22 |
1996-08-29 |
Novartis Ag |
1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
|
MY132550A
(en)
|
1996-08-22 |
2007-10-31 |
Novartis Ag |
Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
|
AU768880B2
(en)
*
|
1999-03-29 |
2004-01-08 |
Bristol-Myers Squibb Company |
Use of vasopeptidase inhibitors to treat angina pectoris
|
US7468390B2
(en)
|
2002-01-17 |
2008-12-23 |
Novartis Ag |
Methods of treatment and pharmaceutical composition
|
ATE370732T1
(de)
*
|
2002-01-17 |
2007-09-15 |
Novartis Pharma Gmbh |
Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
|
GB0203061D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
ATE550656T1
(de)
*
|
2003-08-20 |
2012-04-15 |
Alere San Diego Inc |
Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
|
US7781478B2
(en)
*
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US8013006B2
(en)
*
|
2004-07-14 |
2011-09-06 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7772271B2
(en)
*
|
2004-07-14 |
2010-08-10 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7868037B2
(en)
*
|
2004-07-14 |
2011-01-11 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
JP2008507518A
(ja)
|
2004-07-22 |
2008-03-13 |
ピーティーシー セラピューティクス,インコーポレーテッド |
C型肝炎を治療するためのチエノピリジン
|
MY146830A
(en)
*
|
2005-02-11 |
2012-09-28 |
Novartis Ag |
Combination of organic compounds
|
WO2007045663A2
(en)
*
|
2005-10-19 |
2007-04-26 |
Novartis Ag |
Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
|
AR057882A1
(es)
*
|
2005-11-09 |
2007-12-26 |
Novartis Ag |
Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
|
RU2459809C2
(ru)
*
|
2005-11-09 |
2012-08-27 |
Новартис Аг |
Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
|
EP1903027A1
(en)
*
|
2006-09-13 |
2008-03-26 |
Novartis AG |
Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
|
NZ577910A
(en)
*
|
2007-01-12 |
2012-04-27 |
Novartis Ag |
Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
|
TW200838501A
(en)
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
TWI448284B
(zh)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
TWI406850B
(zh)
*
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
US7834041B2
(en)
|
2007-09-07 |
2010-11-16 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
BRPI0817503B8
(pt)
*
|
2007-10-05 |
2021-05-25 |
Sstarbio Pte Ltd |
derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
|
US8212052B2
(en)
*
|
2007-12-11 |
2012-07-03 |
Theravance, Inc. |
Dual-acting benzoimidazole antihypertensive agents
|
AR070176A1
(es)
*
|
2008-01-17 |
2010-03-17 |
Novartis Ag |
Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
|
AU2012202949B2
(en)
*
|
2008-01-17 |
2015-01-22 |
Novartis Ag |
Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
|
JP2011518884A
(ja)
|
2008-04-29 |
2011-06-30 |
セラヴァンス, インコーポレーテッド |
二重活性抗高血圧剤
|
CN101607875B
(zh)
*
|
2008-06-17 |
2012-07-25 |
中国石油化学工业开发股份有限公司 |
制造环烷酮的方法
|
EP2334651A2
(en)
|
2008-07-24 |
2011-06-22 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101774941A
(zh)
*
|
2009-01-13 |
2010-07-14 |
浙江九洲药业股份有限公司 |
2-酰基氨基-3-联苯基丙酸的制备及拆分方法
|
JP2012526810A
(ja)
|
2009-05-13 |
2012-11-01 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
BRPI1011657A2
(pt)
*
|
2009-05-28 |
2019-04-16 |
Novartis Ag |
derivados aminopropiônicos substituídos como inibidores de neprilisina
|
EA201101672A1
(ru)
*
|
2009-05-28 |
2012-06-29 |
Новартис Аг |
Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
|
US7956054B2
(en)
|
2009-07-07 |
2011-06-07 |
Theravance, Inc. |
Dual-acting pyrazole antihypertensive agents
|
WO2011011232A1
(en)
|
2009-07-22 |
2011-01-27 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
JP2013517295A
(ja)
|
2010-01-19 |
2013-05-16 |
セラヴァンス, インコーポレーテッド |
二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬
|
BR112012017869A2
(pt)
*
|
2010-01-22 |
2019-09-24 |
Novartis Ag |
"intermediários dos inibidores da endopeptidase neutraq e método de preparação dos mesmos"
|
PL2609071T3
(pl)
*
|
2010-08-23 |
2017-03-31 |
Novartis Ag |
Nowy sposób otrzymywania związków pośrednich użytecznych do wytwarzania inhibitorów NEP
|
JP5705984B2
(ja)
*
|
2010-08-23 |
2015-04-22 |
ノバルティス アーゲー |
Nep阻害剤を製造するための中間体の調製方法
|
KR101864865B1
(ko)
|
2010-08-24 |
2018-06-05 |
노파르티스 아게 |
항응고제 요법을 받고 있는 포유동물에서의 고혈압의 치료 및/또는 심부전의 예방 또는 치료
|
US8993631B2
(en)
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8673974B2
(en)
*
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
ES2550324T3
(es)
|
2010-12-15 |
2015-11-06 |
Theravance Biopharma R&D Ip, Llc |
Inhibidores de neprilisina
|
AR084290A1
(es)
|
2010-12-15 |
2013-05-08 |
Theravance Inc |
Inhibidores de neprilisina, metodos para su preparacion e intermediarios utilizados en los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la inhibicion de nep
|
US8481044B2
(en)
|
2011-02-17 |
2013-07-09 |
Theravance, Inc. |
Neprilysin inhibitors
|
US8449890B2
(en)
|
2011-02-17 |
2013-05-28 |
Theravance, Inc. |
Neprilysin inhibitors
|
WO2012166389A1
(en)
|
2011-05-31 |
2012-12-06 |
Theravance, Inc. |
Neprilysin inhibitors
|
WO2012166390A1
(en)
|
2011-05-31 |
2012-12-06 |
Theravance, Inc. |
Neprilysin inhibitors
|
CA2835216A1
(en)
|
2011-05-31 |
2012-12-06 |
Theravance, Inc. |
Neprilysin inhibitors
|
TWI560172B
(en)
|
2011-11-02 |
2016-12-01 |
Theravance Biopharma R&D Ip Llc |
Neprilysin inhibitors
|
AR089955A1
(es)
*
|
2012-02-15 |
2014-10-01 |
Theravance Inc |
Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico
|
JP6088047B2
(ja)
|
2012-05-31 |
2017-03-01 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
一酸化窒素ドナーであるネプリライシン阻害剤
|
RS55967B1
(sr)
|
2012-06-08 |
2017-09-29 |
Theravance Biopharma R&D Ip Llc |
Inhibitori neprilizina
|
ES2710932T3
(es)
|
2012-06-08 |
2019-04-29 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de neprilisina
|
DK2882716T3
(en)
|
2012-08-08 |
2017-03-06 |
Theravance Biopharma R&D Ip Llc |
Neprilysin inhibitors
|
RU2667643C2
(ru)
|
2012-08-24 |
2018-09-21 |
Новартис Аг |
Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
|
CN105008337B
(zh)
|
2013-02-14 |
2017-08-04 |
诺华股份有限公司 |
具有改善的体内功效的作为nep抑制剂的取代的联苯基丁酸衍生物
|
LT2956464T
(lt)
|
2013-02-14 |
2018-07-10 |
Novartis Ag |
Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
|
EP2956141A4
(en)
|
2013-02-17 |
2016-10-26 |
Intra Cellular Therapies Inc |
NEW USES
|
PT2964616T
(pt)
|
2013-03-05 |
2017-08-08 |
Theravance Biopharma R&D Ip Llc |
Inibidores da neprilisina
|
CN104230865B
(zh)
*
|
2013-06-13 |
2018-01-09 |
上海翰森生物医药科技有限公司 |
联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
|
JP2016530282A
(ja)
|
2013-08-26 |
2016-09-29 |
ノバルティス アーゲー |
新規使用
|
ES2767084T3
(es)
|
2013-08-26 |
2020-06-16 |
Novartis Ag |
Nuevo uso
|
EP3099668B1
(en)
|
2014-01-30 |
2022-05-04 |
Theravance Biopharma R&D IP, LLC |
5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
|
AU2015210983B2
(en)
|
2014-01-30 |
2018-10-04 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
CN106795099B
(zh)
*
|
2014-04-10 |
2019-11-26 |
南京奥昭生物科技有限公司 |
用于治疗高血压和心血管疾病的前药和组合物
|
ES2745819T3
(es)
|
2014-08-07 |
2020-03-03 |
Intra Cellular Therapies Inc |
Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
|
CN106458857A
(zh)
*
|
2014-08-27 |
2017-02-22 |
上海翰森生物医药科技有限公司 |
AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
|
CN105622452A
(zh)
*
|
2014-08-27 |
2016-06-01 |
上海翰森生物医药科技有限公司 |
Ahu-377结晶型游离酸及其制备方法和应用
|
CN105461587A
(zh)
*
|
2014-08-27 |
2016-04-06 |
上海翰森生物医药科技有限公司 |
Ahu-377半钙盐晶型及其制备方法和应用
|
CN105367438A
(zh)
*
|
2014-08-27 |
2016-03-02 |
上海翰森生物医药科技有限公司 |
AHU-377α-苯乙胺盐多晶型及其制备方法和应用
|
WO2016037098A1
(en)
|
2014-09-04 |
2016-03-10 |
Concert Pharmaceuticals, Inc. |
Deuterated sacubitril
|
ES2745157T3
(es)
|
2014-11-14 |
2020-02-27 |
Zentiva Ks |
Un método para la preparación, aislamiento y purificación de formas farmacéuticamente aplicables de AHU-377
|
CN105693543B
(zh)
*
|
2014-12-15 |
2018-08-10 |
四川海思科制药有限公司 |
沙库比曲类衍生物、其药物组合物、制备方法及用途
|
CN104557600B
(zh)
*
|
2015-01-26 |
2016-05-04 |
苏州明锐医药科技有限公司 |
沙库比曲的制备方法
|
WO2016130650A1
(en)
|
2015-02-11 |
2016-08-18 |
Theravance Biopharma R&D Ip, Llc |
(2s, 4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
|
TW201632493A
(zh)
|
2015-02-13 |
2016-09-16 |
諾華公司 |
新穎方法
|
RU2715241C2
(ru)
|
2015-02-19 |
2020-02-26 |
ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи |
(2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота
|
WO2016135751A1
(en)
|
2015-02-25 |
2016-09-01 |
Mylan Laboratories Limited |
Novel process for the preparation of sacubitril and its intermediates
|
CN105963296B
(zh)
*
|
2015-03-12 |
2020-01-21 |
深圳信立泰药业股份有限公司 |
一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
|
US10233144B2
(en)
*
|
2015-03-20 |
2019-03-19 |
Crystal Pharmatech Co., Ltd. |
Crystalline form of AHU377, preparation method and use thereof
|
ES2945866T3
(es)
|
2015-05-11 |
2023-07-10 |
Novartis Ag |
Pauta posológica de sacubitrilo-valsartán para el tratamiento de la insuficiencia cardíaca
|
JP2018516267A
(ja)
|
2015-05-29 |
2018-06-21 |
ノバルティス アーゲー |
代謝性疾患を治療するためのサクビトリルおよびバルサルタン
|
CN104860894B
(zh)
*
|
2015-06-10 |
2017-05-17 |
北京博全健医药科技有限公司 |
一种抗心衰药lcz696的制备方法
|
EP3307720A1
(en)
|
2015-06-12 |
2018-04-18 |
Teva Pharmaceuticals International GmbH |
Solid state forms of trisodium valsartan: sacubitril
|
WO2016203500A2
(en)
|
2015-06-19 |
2016-12-22 |
Actavis Group Ptc Ehf. |
Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
|
ES2837084T3
(es)
*
|
2015-07-02 |
2021-06-29 |
Novartis Ag |
Sales de calcio se sacubitril
|
WO2017006254A1
(en)
|
2015-07-08 |
2017-01-12 |
Novartis Ag |
Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
|
WO2017009784A1
(en)
|
2015-07-14 |
2017-01-19 |
Cadila Healthcare Limited |
Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
|
WO2017012600A1
(en)
|
2015-07-20 |
2017-01-26 |
Zentiva, K.S. |
A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
|
WO2017013010A1
(de)
|
2015-07-23 |
2017-01-26 |
Bayer Pharma Aktiengesellschaft |
Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
|
WO2017029261A1
(de)
*
|
2015-08-19 |
2017-02-23 |
Bayer Pharma Aktiengesellschaft |
Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
|
WO2017033128A1
(en)
|
2015-08-25 |
2017-03-02 |
Novartis Ag |
Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
|
WO2017037577A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
New use
|
WO2017051326A1
(en)
|
2015-09-23 |
2017-03-30 |
Novartis Ag |
New processes and intermediates useful in synthesis of nep inhibitors
|
WO2017072636A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical synergistic combination
|
KR20180093984A
(ko)
|
2015-12-10 |
2018-08-22 |
노파르티스 아게 |
신규 방법 및 중간체
|
BR112018011788A2
(pt)
*
|
2015-12-11 |
2018-12-04 |
Zentiva Ks |
formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
|
CN106977417A
(zh)
*
|
2016-01-15 |
2017-07-25 |
常州方楠医药技术有限公司 |
一种沙库比曲钠盐的晶型及其制备方法
|
AU2017215530B2
(en)
|
2016-02-03 |
2019-09-12 |
Novartis Ag |
Galenic formulations of organic compounds
|
JP7306828B2
(ja)
|
2016-03-08 |
2023-07-11 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
結晶性(2s,4r)-5-(5’-クロロ-2’-フルオロ-[1,1’-ビフェニル]-4-イル)-2-(エトキシメチル)-4-(3-ヒドロキシイソオキサゾール-5-カルボキサミド)-2-メチルペンタン酸およびその使用
|
EP3436083A4
(en)
|
2016-03-28 |
2019-11-27 |
Intra-Cellular Therapies, Inc. |
NEW COMPOSITIONS AND METHODS
|
CN105753733B
(zh)
*
|
2016-04-15 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
Ahu377的晶型及其制备方法与用途
|
CN105820064A
(zh)
*
|
2016-04-18 |
2016-08-03 |
浙江天宇药业股份有限公司 |
一种联苯基丙氨醇衍生物的合成方法及中间体
|
WO2017191620A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Sun Pharmaceutical Industries Limited |
A crystalline form of a salt of sacubitril and a process of its preparation
|
JP6944473B2
(ja)
*
|
2016-07-05 |
2021-10-06 |
ノバルティス アーゲー |
初期サクビトリル中間体のための新規な方法
|
CN107602399B
(zh)
*
|
2016-07-11 |
2020-09-25 |
江西东邦药业有限公司 |
一种脑啡肽酶抑制剂中间体的制备方法
|
WO2018033866A1
(en)
|
2016-08-17 |
2018-02-22 |
Novartis Ag |
New processes and intermediates for nep inhibitor synthesis
|
CN106318988B
(zh)
*
|
2016-08-23 |
2020-11-03 |
迪嘉药业集团有限公司 |
一种lcz696关键中间体的制备方法
|
EP3511317A4
(en)
*
|
2016-09-07 |
2020-04-15 |
Noratech Pharmaceuticals, Inc. |
NEW CRYSTALLINE SODIUM SALT FORM OF SACUBITRIL
|
CN106478437A
(zh)
*
|
2016-09-27 |
2017-03-08 |
南通常佑药业科技有限公司 |
一种γ‑氨基戊酸酯衍生物的制备方法
|
CN106496055A
(zh)
*
|
2016-10-09 |
2017-03-15 |
杭州科巢生物科技有限公司 |
一种抗心衰新药的关键组分沙库比曲的新合成方法
|
WO2018069833A1
(en)
*
|
2016-10-10 |
2018-04-19 |
Laurus Labs Limited |
Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
|
KR20190077467A
(ko)
|
2016-10-28 |
2019-07-03 |
바이오콘 리미티드 |
비정질 삼나트륨 사쿠비트릴 발사르탄 및 이의 제조방법
|
US10774036B2
(en)
|
2016-12-23 |
2020-09-15 |
Novartis Ag |
Process for early sacubitril intermediates
|
CN106831473B
(zh)
*
|
2017-02-22 |
2019-07-16 |
江西瑞雅药业有限公司 |
3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
|
WO2018153895A1
(de)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
|
WO2018178295A1
(en)
|
2017-03-31 |
2018-10-04 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Stable hot-melt extrudate containing valsartan and sacubitril
|
WO2019020706A1
(en)
|
2017-07-28 |
2019-01-31 |
Synthon B.V. |
PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
|
US20200276129A1
(en)
|
2017-10-13 |
2020-09-03 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Tablet containing valsartan and sacubitril
|
WO2019127994A1
(zh)
*
|
2017-12-27 |
2019-07-04 |
浙江天宇药业股份有限公司 |
一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
UY38072A
(es)
*
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201810326D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Johnson Matthey Plc |
Crystalline form of sacubitril, its preparation and use
|
WO2020039386A1
(en)
|
2018-08-23 |
2020-02-27 |
Novartis Ag |
New pharmaceutical use for the treatment of heart failure
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN109503404A
(zh)
*
|
2018-12-28 |
2019-03-22 |
凯瑞斯德生化(苏州)有限公司 |
一种lcz-696关键中间体的制备方法
|
CN110128298B
(zh)
*
|
2019-06-13 |
2021-08-03 |
南京一心和医药科技有限公司 |
一种沙库巴曲中间体的合成方法
|
CN113135836A
(zh)
*
|
2020-01-20 |
2021-07-20 |
鲁南制药集团股份有限公司 |
一种沙库巴曲钙盐的制备方法
|
CN111253425B
(zh)
*
|
2020-02-21 |
2022-04-29 |
常州南京大学高新技术研究院 |
一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
|
JP7064527B2
(ja)
*
|
2020-05-01 |
2022-05-10 |
ノバルティス アーゲー |
サクビトリルカルシウム塩
|
KR20220012821A
(ko)
|
2020-07-23 |
2022-02-04 |
주식회사 종근당 |
이중 작용 복합 화합물의 결정형 및 이의 제조방법
|
CN112661671B
(zh)
*
|
2020-12-22 |
2022-04-22 |
江苏阿尔法药业股份有限公司 |
一种沙库巴曲中间体的制备方法
|
WO2022224274A1
(en)
|
2021-04-20 |
2022-10-27 |
Mylan Laboratories Limited |
Polymorphic forms of sacubitril-telmisartan (1:1)
|